Financial Contrast: Charles River Laboratories International (CRL) versus The Competition

Charles River Laboratories International (NYSE: CRL) is one of 197 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Charles River Laboratories International to related companies based on the strength of its dividends, earnings, institutional ownership, profitability, risk, analyst recommendations and valuation.

Institutional and Insider Ownership

95.1% of Charles River Laboratories International shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 2.2% of Charles River Laboratories International shares are owned by insiders. Comparatively, 14.0% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Risk and Volatility

Charles River Laboratories International has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Charles River Laboratories International’s peers have a beta of 1.63, meaning that their average share price is 63% more volatile than the S&P 500.

Valuation & Earnings

This table compares Charles River Laboratories International and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Charles River Laboratories International $1.81 billion $435.89 million 29.94
Charles River Laboratories International Competitors $207.78 million -$2.31 million 0.51

Charles River Laboratories International has higher revenue and earnings than its peers. Charles River Laboratories International is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Charles River Laboratories International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Charles River Laboratories International 10.13% 27.02% 8.84%
Charles River Laboratories International Competitors -3,984.80% -117.96% -44.22%

Analyst Ratings

This is a summary of recent ratings and price targets for Charles River Laboratories International and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Charles River Laboratories International 0 5 4 0 2.44
Charles River Laboratories International Competitors 475 2250 6143 119 2.66

Charles River Laboratories International currently has a consensus target price of $103.17, suggesting a potential downside of 9.56%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 0.65%. Given Charles River Laboratories International’s peers stronger consensus rating and higher probable upside, analysts plainly believe Charles River Laboratories International has less favorable growth aspects than its peers.

Summary

Charles River Laboratories International beats its peers on 7 of the 13 factors compared.

About Charles River Laboratories International

Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company’s clients’ manufacturing activities.

Receive News & Ratings for Charles River Laboratories International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston’s Dallas Keuchel Could Make Relief Appearance in Game 7
Houston Astros Relying on Justin Verlander to Save Their Season
Houston Astros Relying on Justin Verlander to Save Their Season
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Clayton Kershaw Gets Chance to Pitch LA into Fall Classic
Aaron Judge and Gary Sanchez Have Break Out Games
Aaron Judge and Gary Sanchez Have Break Out Games
Justin Turner Joining Postseason Legends
Justin Turner Joining Postseason Legends
PED Use Cost Alex Rodriguez Millions and His Reputation
PED Use Cost Alex Rodriguez Millions and His Reputation


Leave a Reply

 
© 2006-2017 BBNS.